CASE REPORT

Tuberculosis epididymo-orchitis following intravesical bacillus Calmette-Guérin immunotherapy

Sean Rezvani* and Gerald Collins

Stockport NHS Foundation Trust, Poplar Grove, Hazel Grove, Stockport SK2 7JE, UK

*Correspondence address. Stockport NHS Foundation Trust, Poplar Grove, Hazel Grove, Stockport SK2 7JE, UK. Tel: +0161 483 1010; E-mail: sean.rezvani@doctors.org.uk

Abstract

BCG is a well-established treatment for superficial bladder cancer. Although usually well-tolerated, side effects can range from mild cystitis to life-threatening sepsis. Epididymitis is a rare complication of BCG, with only a handful of cases proven to be caused directly by Mycobacterium bovis. We describe one such case, along with radiological findings for this rare complication.

INTRODUCTION

Intravesical Bacillus Calmette-Guérin (BCG) is a long-established and proven therapy for treatment and prevention of G2T1 and G3 Ta/T1 bladder transitional cell carcinoma (TCC) and carcinoma in situ (CIS). Although generally well tolerated, complications of having been reported, ranging from cystitis, myalgia and pyrexia to life threatening and fatal sepsis [1]. Tuberculous-epididymitis following intravesical BCG has only been reported in a handful of cases. We describe one such case, along with radiological findings and a review of the literature for this rare complication.

CASE REPORT

A 73-year-old patient with a history of previous transurethral resection (TUR) of the prostate, presented with dysuria and urinary infection and was found to have an intravesical lesion on flexible cystoscopy. As part of his work up, a CT urogram was performed but no upper tract abnormalities were detected.

He underwent TUR for this lesion which histological analysis revealed to be a G3 pT1 bladder TCC. Subsequent cystoscopy and re-resection showed further G3 pT1 disease and CIS.

To prevent further recurrence, the patient was offered adjuvant intravesical BCG immunotherapy, and he completed a 6-week course of treatment without complication. He was followed up after completing this course of BCG with flexible cystoscopy, which showed only generalized inflammation but no recurrence.

Three months later, a further 3-dose maintenance course of intravesical BCG was given, after which the patient began experience right sided testicular pain and swelling. He was treated for epididymitis with a prolonged course of oral antibiotics and anti-inflammatory medication.

At a further check cystoscopy 1 month later, it was noted the patient continued to have right scrotal swelling and pain, as well as pus extruding from a sinus in the scrotal skin.

Ultrasound scanning of the scrotum revealed a heterogenous focus of tissue calcification within the right epididymal tail, and inflammatory changes associated with granulomatous change (Fig. 1a and b).

A pus swab yielded a negative result for acid fast bacilli under microscopy, but a positive result for Mycobacterium bovis variant using whole genome sequencing. He was subsequently commenced on a 6 month course of isoniazid, rifampicin and ethambutol as guided by antibiotic sensitivities, and referred to a local infectious diseases unit.
Demers and Pelsser point out that heterogeneity in testicular malignancy is not usually accompanied by epididymal enlargement in the early stages until there is direct extension of tumour [3]. Commonly, other cases in the literature have described diagnosis through histological analysis following orchidectomy, where testicular malignancy was suspected [4]. Some have advocated the use of biopsy prior to orchidecomy in cases where tuberculous-epididymitis forms part of any differential diagnosis [3].

Post BCG-immunotherapy infections can vary widely in their presentation and incubation. Clinicians should have a high index of suspicion in any patient with infective symptoms, especially those who fail to respond to conventional antibiotics.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596–600.
2. Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007;61:299–305.
3. Demers V, Pelsser V. ‘BCGitis’: a rare case of tuberculous epididymo-orchitis following intravesical Bacillus Calmette-Guerin therapy. J Radiol Case Rep 2012;6:16–21.
4. Parker SG, Kommu SS. Post-intravesical BCG epididymo-orchitis: case report and a review of the literature. Int J Surg Case Rep 2013;4:768–70.
5. El Hamrouni I, Puttemans T, Dardenne E, Draguet AP. Unusual case of testicular tuberculosis. J Belg Soc Radiol 2017;101:17.
6. Briceno-Garcia EM, Gomez-Pardal A, Alvarez-Bustos G, Artero-Munoz I, Molinero MM, Seara-Valero R, et al. Tuberculous orchiepididymitis after BCG therapy for bladder cancer. J Ultrasound Med 2007;26:977–9.
7. Muttarak M, Peh WC. Case 91: tuberculous epididymo-orchitis. Radiology 2006;238:748–51.